Volition’s initial Nu.Q™ products are focusing on colorectal cancer. Colorectal cancer is responsible for over 200,000 deaths in Europe each year, almost 50,000 deaths in the USA and nearly 700,000 deaths worldwide.
Products in development
- Interim results of a panel of 4 Nu.Q™ assays detected 81% of colorectal cancers at 78% specificity in a cohort of 4800 symptomatic patients.
- A panel of 4 normalised Nu.Q™ assays detected 67% of high risk adenomas at 80% specificity in a cohort of 530 symptomatic patients.
- A panel of 4 Nu.Q™ assays detected 74% sensitivity at 90% specificity in a pilot study of 58 asymptomatic patients, detecting 75% of early stage I cancers.
There is a clear medical need for a reliable, simple, and accurate diagnostic test for pancreatic cancer. Currently, emergency presentation is the most common route to diagnosis, and only 21% of patients survive for more than a year.
- A panel of 4 Nu.Q™ assays plus CA19-9 in a pilot study of 59 patients detected 92% of pancreatic cancers at 100% specificity
- Interim results of a panel of 2 Nu.Q™ assays plus CEA detected 95% of pancreatic cancers at 84% specificity.
Lung cancer is the most common cancer worldwide. Only 10% of lung cancer patients will survive for five years or more. Current screening methods for lung cancer are widely regarded as too inaccurate and expensive for widespread use.
- A panel of 4 Nu.Q™ assays in a pilot study of 73 patients detected 93% of lung cancers at 91% specificity.
Ongoing clinical trials
|Hvidore Hospital, University of Copenhagen||Colorectal cancer||Retrospective||4,800 sympomatic|
|Hvidore Hospital, University of Copenhagen||Colorectal cancer||Prospective||14,000 screening population|
|Hvidore Hospital, University of Copenhagen||Colorectal cancer and other||Prospective, longitudinal||30,000 screening population to provide 3 samples (90,000 samples total)|
|University of Bonn||27 most prevalent cancers||Prospective||4,700|
|German Cancer Research Center (DKFZ)||Pancreatic||Restrospective||750|